For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Substudy
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Using SMART to optimize the stepped care delivery of TEMPO – a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers (TEMPO)
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
Congratulations to our colleague Dr. Frances Shepherd, medical oncologist at Princess Margaret Cancer Centre, who has received the prestigious 2018 Canada Gairdner Wightman Award "for her global leadership in oncology which has contributed significantly to the improving survival outcome of lung cancer patients worldwide." Dr. Shepherd served as Chair of the Lung Cancer Committee at CCTG for 19 years!
The MAC.23 trial a Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation with Breast Reconstruction has been centrally activated
On-line Registration is now open. Travel and hotel information, a draft Schedule of Events, and our meetings policies, including the Invitation Policy, Registration Policy, and Travel Reimbursement Policy, are posted on the Spring Meeting 2018 Registration and Information page.
Queen's University played host to a research funding announcement with Dr. John Fisher, Vice-Principal (Research), Queen’s University and Ms. Sophie Kiwala, MPP for Kingston and the Islands. Along with a number of awards, it was announced that CCTG has received matching infrastructure funding from The Ontario Research Fund to support the purchase of a histology slide scanner.
Dr. John Hilton, the Study Co-Chair of IND.231, gave an oral presentation of the results to date from IND.231, A Phase I/II Study of CX-5461, at the Targeted Anti-Cancer Therapies (TAT) International Congress 2018
